Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Pulmonary Arterial HypertensionIdiopathic Pulmonary Fibrosis
Interventions
DRUG

Inhaled Nitric Oxide

Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM

DRUG

Inhaled Nitric Oxide

Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM

DRUG

Inhaled Nitric Oxide

Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM

Trial Locations (10)

35294

University of Alabama @ Birmingham, Birmingham

40204

Kentuckiana Pulmonary Associates, Louisville

43221

Ohio State University, Martha Morehouse Medical Plaza, Columbus

63110

Washington University School of Medicine, St Louis

75239

UT Southwestern Medical Center, Dallas

80206

National Jewish Health, Denver

84132

University of Utah, Salt Lake City

90073

VA Greater LA Health Care System-UCLA, Los Angeles

95817

University of California- Davis Medical Center, Sacramento

07103

University of Medicine and Dentistry of New Jersey, Newark

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Geno LLC

INDUSTRY